TY - JOUR
T1 - Adriamycin
T2 - A new effective agent in the therapy of disseminated sarcomas
AU - Benjamin, Robert S.
AU - Wiernik, Peter H.
AU - Bachur, Nicholas R.
PY - 1975
Y1 - 1975
N2 - Thirty‐six patients with disseminated sarcomas were treated with adriamycin according to an intermittent single high‐dosage schedule based on our prior pharmacologic observations. The dose of 60 mg/M2 IV q 3 weeks was reduced 50‐75% in the presence of liver disease. Complete remission occurred in 9%, partial remission in 32%, and improvement in 21% for median durations of 37, 18, and 15 weeks, respectively. Survival was prolonged in responding patients. Hematologic suppression was mild in the absence of liver disease or prior extensive radiotherapy. Congestive heart failure, a well‐known long‐term complication of therapy with anthracycline drugs, occurred in two out of four patients who had cumulative doses of 600 mg/M2 or more. Mucous membrane toxicity was not observed. Adriamycin is an effective new agent in the therapy of disseminated sarcomas and can be used with relative safety by following pharmacologic principles.
AB - Thirty‐six patients with disseminated sarcomas were treated with adriamycin according to an intermittent single high‐dosage schedule based on our prior pharmacologic observations. The dose of 60 mg/M2 IV q 3 weeks was reduced 50‐75% in the presence of liver disease. Complete remission occurred in 9%, partial remission in 32%, and improvement in 21% for median durations of 37, 18, and 15 weeks, respectively. Survival was prolonged in responding patients. Hematologic suppression was mild in the absence of liver disease or prior extensive radiotherapy. Congestive heart failure, a well‐known long‐term complication of therapy with anthracycline drugs, occurred in two out of four patients who had cumulative doses of 600 mg/M2 or more. Mucous membrane toxicity was not observed. Adriamycin is an effective new agent in the therapy of disseminated sarcomas and can be used with relative safety by following pharmacologic principles.
UR - http://www.scopus.com/inward/record.url?scp=0016713762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0016713762&partnerID=8YFLogxK
U2 - 10.1002/mpo.2950010109
DO - 10.1002/mpo.2950010109
M3 - Article
C2 - 1232527
AN - SCOPUS:0016713762
SN - 0098-1532
VL - 1
SP - 63
EP - 76
JO - Medical and Pediatric Oncology
JF - Medical and Pediatric Oncology
IS - 1
ER -